Search research articles
Contact Us
Filters
Showing results (31-40 of 477) with videos related to
Page
of 48
Sort By:
Current Opinion in Rheumatology
|
April 23, 2003
Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?
Yolanda Braun-Moscovici, Daniel E Furst
Rheumatic Diseases Clinics of North America
|
March 21, 2007
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient
Veena K Ranganath, Daniel E Furst
Best Practice & Research. Clinical Rheumatology
|
December 11, 2007
Connective tissue diseases
Daniel E Furst, Marco Matucci Cerinic
Current Opinion in Rheumatology
|
April 23, 2003
Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it?
Yolanda Braun-Moscovici, Daniel E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
September 24, 2016
The Responsibilites of Daily Life May Interfere With Adherence to Medications in Patients With Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc)
M Cameron Hay, Daniel E Furst
Arthritis and Rheumatism
|
April 13, 2004
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
Dinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Drug Metabolism & Toxicology
|
July 26, 2006
Meloxicam in rheumatoid arthritis
Mansoor Ahmed, Dinesh Khanna, Daniel E Furst
Lancet (London, England)
|
May 23, 2006
Systemic sclerosis: hypothesis-driven treatment strategies
Christina Charles, Philip Clements, Daniel E Furst
Drug Safety
|
April 6, 2004
Safety of tumour necrosis factor-alpha antagonists
Dinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Biological Therapy
|
May 20, 2015
Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis
Erin Bauer, Jessica Lucier, Daniel E Furst
Page
of 48
Search research articles
Search
Showing results (31-40 of 477) with videos related to
Sort By:
Page
of 48
Current Opinion in Rheumatology
|
April 23, 2003
Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?
Yolanda Braun-Moscovici, Daniel E Furst
Rheumatic Diseases Clinics of North America
|
March 21, 2007
Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient
Veena K Ranganath, Daniel E Furst
Best Practice & Research. Clinical Rheumatology
|
December 11, 2007
Connective tissue diseases
Daniel E Furst, Marco Matucci Cerinic
Current Opinion in Rheumatology
|
April 23, 2003
Plasmapheresis for rheumatic diseases in the twenty-first century: take it or leave it?
Yolanda Braun-Moscovici, Daniel E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
September 24, 2016
The Responsibilites of Daily Life May Interfere With Adherence to Medications in Patients With Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc)
M Cameron Hay, Daniel E Furst
Arthritis and Rheumatism
|
April 13, 2004
Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here?
Dinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Drug Metabolism & Toxicology
|
July 26, 2006
Meloxicam in rheumatoid arthritis
Mansoor Ahmed, Dinesh Khanna, Daniel E Furst
Lancet (London, England)
|
May 23, 2006
Systemic sclerosis: hypothesis-driven treatment strategies
Christina Charles, Philip Clements, Daniel E Furst
Drug Safety
|
April 6, 2004
Safety of tumour necrosis factor-alpha antagonists
Dinesh Khanna, Maureen McMahon, Daniel E Furst
Expert Opinion on Biological Therapy
|
May 20, 2015
Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis
Erin Bauer, Jessica Lucier, Daniel E Furst
Page
of 48